Skip to main content

Determinants of plasma concentrations of nicotine and cotinine during cigarette smoking and transdermal nicotine treatment

European Journal of Clinical Pharmacology volume 51, pages 407–414 (1997)Cite this article

Abstract

Objective

Interindividual variability in plasma concentrations of nicotine and its proximate metabolite, cotinine, is considerable during smoking and transdermal nicotine treatment, even among individuals taking in nominally similar doses of nicotine. This report explores the determinants of this variability and the utility of baseline (smoking) plasma concentrations to predict concentrations during transdermal nicotine treatment.

Methods

Data were analysed from a smoking cessation study (n = 466), and from a pharmacokinetic study (n = 12). Multiple regression models examined the relationships of plasma concentrations to individual characteristics such as smoking pattern, absorbed dose of nicotine, and pharmacokinetic parameters.

Results

Plasma concentrations of nicotine and cotinine were highly variable in both studies. Indirect estimates of plasma clearance (baseline plasma concentration divided by cigarettes per day) together with other factors could account for 18 to 33% of the variability during transdermal nicotine treatment in the smoking cessation study. In contrast, 75 to 99% was accounted for by direct measurements of plasma clearances and systemic dose of nicotine in the pharmacokinetic study.

Conclusion

Plasma concentrations of nicotine and cotinine during transdermal nicotine treatment are poorly predicted by clinical history or baseline plasma concentrations. This is a result of inadequate characterisation of highly variable individual pharmacokinetic parameters and absorbed dose of nicotine. Considering the interindividual variability of plasma nicotine and cotinine concentrations together with the lack of clinical end-points for transdermal nicotine dosing, it seems logical to investigate the utility of a therapeutic drug monitoring approach for transdermal nicotine treatment — particularly for high dose regimens (> 22 mg per 24 hours).

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Benowitz NL, Jacob III P, Yu L, Talcott R, Hall S, Jones RT (1986) Reduced tar, nicotine, and carbon monoxide exposure while smoking ultralow — but not low-yield cigarettes. JAMA 256: 241–246

    PubMed  Article  CAS  Google Scholar 

  2. Coultas DB, Stidley CA, Samet JM (1993) Cigarette yields of tar and nicotine and markers of exposure to tobacco smoke. Am Rev Resp Dis 148: 435–40

    PubMed  CAS  Google Scholar 

  3. Nørregaard J, Tønnesen P, Peterson L (1993) Predictors and reasons for relapse in smoking cessation with nicotine and placebo patches. Prev Med 22: 261–271

    PubMed  Article  Google Scholar 

  4. Tønnesen P, Nørregaard J, Simonsen K, Säwe U (1991) A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation. N Engl J Med 325: 311–15

    PubMed  Article  Google Scholar 

  5. Stapleton JA, Russell MAH, Feyerabend C, Wiseman SM, Gustavsson G, Sawe U (1995) Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice. Addiction 90: 31–2

    PubMed  Article  CAS  Google Scholar 

  6. Benowitz NL, Jacob III P (1994) Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin Pharm Ther 56: 483–193

    CAS  Google Scholar 

  7. Benowitz NL, Jacob III P (1984) Daily intake of nicotine during cigarette smoking. Clin Pharmacol Ther 35: 499–504

    PubMed  CAS  Google Scholar 

  8. Hurt RD, Dale LC, Offord KP et al. (1993) Serum nicotine and cotinine levels during nicotine patch therapy. Clin Pharm Ther 54: 98–106

    CAS  Google Scholar 

  9. Hurt RD, Dale LC, Fredrickson PA et al. (1994) Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up: one year outcome and percentage of nicotine replacement. JAMA 271: 595–600

    PubMed  Article  CAS  Google Scholar 

  10. Benowitz NL, Jacob III P, Olsson P, Johansson C-J (1992) Intravenous nicotine retards transdermal absorption of nicotine: evidence of blood flow-limited percutaneous absorption. Clin Pharm Ther 52: 223–230

    CAS  Google Scholar 

  11. Sachs DP, Benowitz NL, Bostrum AG, Hansen MD (1995) Percent serum replacement and success of nicotine patch therapy. Am J Respir Crit Care Med 151: A688

    Google Scholar 

  12. Gourlay SG, Forbes A, Marriner T, Pethica D, McNeil JJ (1994) A prospective study of factors predicting smoking cessation using transdermal nicotine therapy. BMJ 309: 842–846

    PubMed  CAS  Google Scholar 

  13. Drummer OH, Horomidis S, Kourtis S, Syrjanen ML, Tippett P (1994) Capillary gas Chromatographic drug screening for use in forensic toxicology. J Analytical Toxicol 18: 134–138

    CAS  Google Scholar 

  14. Jacob III P, Wilson M, Benowitz NL (1981) Improved gas Chromatographic method for the determination of nicotine and cotinine in biologic fluids. J Chromatog, Biomed Applications 222: 61–70

    Article  CAS  Google Scholar 

  15. Jacob III P, Yu L, Wilson M, Benowitz NL (1991) Selected ion monitoring method for determination of nicotine, cotinine, and deuterium-labelled analogues: absence of an isotope effect in the clearance of (s)-nicotine-3’,3’-d2 in humans. Biol Mass Spectrometry 20: 247–252

    Article  CAS  Google Scholar 

  16. Therapeutic Goods Administration (1991) Good Clinical Research Practice Guidelines. Australian Department of Community Services and Health, Canberra.

  17. Gourlay SG, McNeil JJ (1990) Antismoking Products.Med J Aust 153: 699–707

    PubMed  CAS  Google Scholar 

  18. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom K-O (1991) The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Brit J Addict 86: 1119–1127

    Article  CAS  Google Scholar 

  19. Gori GB, Lynch CJ (1985) Analytical cigarette yields as predictors of smoke bioavailability. Regulatory Toxicol & Pharmacol 5: 314–326

    Article  CAS  Google Scholar 

  20. Russell MAH, Jarvis M, Iyer R, Feyerabend C (1980) Relation of nicotine yield of cigarettes to blood nicotine concentrations in smokers. Br Med J i: 972–976

    Article  Google Scholar 

  21. Transdermal nicotine study group. Transdermal nicotine for smoking cessation. JAMA 266: 3133–3138

  22. Jorenby DE, Smith SS, Fiore MC et al. (1995) Varying nicotine patch dose and type of smoking cessation counseling. JAMA 274: 1347–1352

    PubMed  Article  CAS  Google Scholar 

  23. Dale LC, Hurt RD, Offord KP, Lawson GM, Croghan IT, Schroeder DR (1995) High dose nicotine patch therapy: percentage of replacement and smoking cessation. JAMA 274: 1353–1358

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. UCSF Division of Clinical Pharmacology and Experimental Therapeutics, Room 375, UCSF, Box 0898, 94143-0898, San Francisco, CA, USA

    S. G. Gourlay & N. L. Benowitz

  2. Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia

    S. G. Gourlay, A. Forbes & J. J. McNeil

Authors
  1. S. G. Gourlay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. L. Benowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Forbes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. J. McNeil
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Gourlay, S.G., Benowitz, N.L., Forbes, A. et al. Determinants of plasma concentrations of nicotine and cotinine during cigarette smoking and transdermal nicotine treatment. Eur J Clin Pharmacol 51, 407–414 (1997). https://doi.org/10.1007/s002280050222

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002280050222

Key words

  • Transdermal
  • Nicotine
  • Plasma concentrations
  • Cotinine
  • Smoking cessation